ZyVersa Therapeutics Stock (NASDAQ:ZVSA)
Previous Close
$0.14
52W Range
$0.11 - $3.37
50D Avg
$0.26
200D Avg
$0.76
Market Cap
$1.16M
Avg Vol (3M)
$4.11M
Beta
0.72
Div Yield
-
ZVSA Company Profile
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.